Analysis of residual plastic deformation of blanked sheets out of automotive aluminium alloys through hardness map

Reducing overall vehicle weight is essential to reduce fuel consumption and pollutant emission and to improve noise, vibration, and harshness (NVH) performances. The substitution with lighter alloys can involve the grand majority of vehicle components, depending on the market sector. In several applications, e.g., chassis, pulleys, and viscodampers, metal sheets are formed in several steps, each of whom work-hardens the material reducing the available residual plasticity. Typically, the process is designed via FEM, whose results are affected by the initial conditions, often neglected, and is performed on pre-processed materials from suppliers. In this regard, correctly simulating the first step of the process is critical. However, the related initial conditions, in terms of residual stress and strain induced by former preliminary operations, are often neglected. This work proposes a quick and economical experimental procedure based on a hardness map to estimate initial conditions and to validate FEM results. The procedure allows evaluating the material's residual plasticity, which is necessary to process engineers to design following manufacturing steps. The approach is demonstrated on an industrially relevant case study, i.e., the blanking of an AA 5754, in use for water pump pulleys

Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases

Purpose: SBRT demonstrated to increase survival in oligometastatic patients. Nevertheless, little is known regarding the natural history of oligometastatic disease (OMD) and how SBRT may impact the transition to the polymetastatic disease (PMD). Methods: 97 liver metastases in 61 oligometastatic patients were treated with SBRT. Twenty patients (33%) had synchronous oligometastases, 41 (67%) presented with metachronous oligometastases. Median number of treated metastases was 2 (range 1–5). Results: Median follow-up was 24 months. Median tPMC was 11 months (range 4–17 months). Median overall survival (OS) was 23 months (range 16–29 months). Cancer-specific survival predictive factors were having further OMD after SBRT (21 months versus 15 months; p = 0.00), and local control of treated metastases (27 months versus 18 months; p = 0.031). Median PFS was 7 months (range 4–12 months). Patients with 1 metastasis had longer median PFS as compared to those with 2–3 and 4–5 metastases (14.7 months versus 5.3 months versus 6.5 months; p = 0.041). At the last follow-up, 50/61 patients (82%) progressed, 16 of which (26.6%) again as oligometastatic and 34 (56%) as polymetastatic. Conclusion: In the setting of oligometastatic disease, SBRT is able to delay the transition to the PMD. A proportion of patients relapse as oligometastatic and can be eventually evaluated for a further SBRT course. Interestingly, those patients retain a survival benefit as compared to those who had PMD. Further studies are needed to explore the role of SBRT in OMD and to identify treatment strategies able to maintain the oligometastatic state. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature